Jack Henningfield, PhD
- PhD, Psychopharmacology and Experimental Psychology, University of Minnesota, Minnesota, USA, 1977
- Professor (Adjunct), Behavioural Biology, Johns Hopkins University School of Medicine, 2002
- Faculty member, Department of Psychiatry and Behavioural Sciences, Johns Hopkins University School of Medicine, 1978
- Vice President Research and Health Policy, Pinney Associates, Bethesda, Maryland, providing consulting to pharmaceutical developers (including tobacco dependence treatment) and public health organizations pertaining to science, health, regulatory, and policy issues, since 1996
- Director, Robert Wood Johnson Foundation, Innovators Combating Substance Abuse Awards Program at Johns Hopkins University School of Medicine
- Pharmacologist and Chief, Clinical Pharmacology Research Branch, Biology of Dependence and Abuse Potential Assessment Laboratory, and Human Performance Laboratory, US National Institute on Drug Abuse, 1980-1996
- Research experience in behavioural, cognitive, and central nervous system effects of various drugs and drug formulations including alcohol, barbiturates, anticholinergics, marijuana, nicotine, opioids, stimulants and tobacco products
- Chair/member/rapporteur, numerous US national and international committees and study groups pertaining to drug addiction, drug testing, medications evaluations, abuse liability and research review (US Food and Drug Administration, US Centers for Disease Control, National Institutes of Health; Expert Committees and Advisory groups for Canada, UK, EU and WHO)
- Scientific Editor, 1988 US Surgeon General’s Report: Nicotine Addiction
- Published more that 300 articles, reviews, and books related to drug addiction: approximately 60% specifically related to tobacco and nicotine
- Past President, Society for Research on Nicotine and Tobacco,
- Past Vice President, International Study Group Investigating Drugs as Reinforcers